We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche’s rheumatoid arthritis blockbuster Actemra (tocilizumab) showed no benefit for hospitalized COVID-19 patients in a phase 3 trial, but the company still has high hopes for the drug as a potential treatment for COVID-19 infections. Read More
AstraZeneca is expanding its oncology product portfolio with a $6 billion development and commercialization agreement for Daiichi Sankyo’s investigational cancer treatment DS-1062. Read More
Pfizer and BioNTech began a phase 2/3 trial yesterday of one of their COVID-19 vaccine candidates, but not the one originally considered to be the most promising. Read More
Moderna has begun a much-anticipated phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 — the first phase 3 trial of a coronavirus vaccine in the U.S. Read More